Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model
<p><strong>Background</strong> Despite widespread searches, there are currently no validated biofluid markers for the detection of subclinical neuroinflammation in multiple sclerosis (MS). The dynamic nature of human metabolism in response to changes in homeostasis, as measured by...
Main Authors: | Yeo, T, Bayuangga, H, Augusto-Oliveira, M, Sealey, M, Claridge, TDW, Tanner, RL, Leppert, D, Palace, J, Kuhle, J, Probert, F, Anthony, DC |
---|---|
Format: | Journal article |
Language: | English |
Published: |
BioMed Central
2022
|
Similar Items
-
Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model
by: Yeo, Tianrong, et al.
Published: (2022) -
Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis
by: Probert, F, et al.
Published: (2021) -
Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach
by: Yeo, T, et al.
Published: (2021) -
Classifying the antibody-negative NMO syndromes: Clinical, imaging, and metabolomic modeling
by: Yeo, T, et al.
Published: (2019) -
Determination of CSF GFAP, CCN5, and vWF levels enhances the diagnostic accuracy of clinically defined MS from non-MS patients with CSF oligoclonal bands
by: Probert, F, et al.
Published: (2022)